Upregulation of Monocyte  Chemoattractant Protein-1 (MCP-1) in Early
Diabetic Nephropathy in Patients with Type-1 Diabetes Mellitus

El-Shafey, Eid; El-Nagar, G. F.; Abu Hatab, Hasan; Sabry, Alaa; Elbaz, Hesham

doi:https://doi.org/10.3814/2008/467264

Scholarly Research Exchange

On this page

Abstract References Copyright Related Articles

Clinical Study | Open Access

Volume 2008 | Article ID 467264 | https://doi.org/10.3814/2008/467264

Upregulation of Monocyte Chemoattractant Protein-1 (MCP-1) in Early Diabetic Nephropathy in Patients with Type-1 Diabetes Mellitus

Eid El-Shafey,¹G. F. El-Nagar,¹Hasan Abu Hatab,²Alaa Sabry,³and Hesham Elbaz⁴

Received25 Jun 2008

Accepted10 Sept 2008

Published24 Nov 2008

Abstract

Background. Monocyte chemoattractant protein-1 (MCP-1) can directly elicit an inflammatory response by inducing cytokine and adhesion molecule expression in the kidney. We investigated the role of MCP-1 in the development of early nephropathy in patients with type-1 diabetes mellitus, in addition to the effect of high-dose vitamin E treatment (8 weeks) on early stages of diabetic nephropathy. Methods. This study was carried out on 30 type-1 diabetic patients subdivided into two equal groups according to their urinary albumin excretion, in addition to 10 healthy matched volunteers included as controls. MCP-1, glycated hemoglobin (HbA1c), and albuminuria—before and after vitamin E treatment—were measured in all studied groups. Results. Serum MCP-1 and HbA1c were significantly elevated in patients with microalbuminuria and poor glycemic control (941.67±47.03 pg/mL; 16.95±2.74%) compared to normoalbuminuric diabetic patients (622.73±103.23 pg/mL; 7.23±0.86%), and controls (366.60±129.01; 3.35±0.66) (P=.001), respectively. There was positive correlation between MCP-1 and HbA1c. Both MCP-1 and albuminuria decreased significantly after using high-dose vitamin E treatment, though there was no change in HbA1c in type-1 diabetic patients with early nephropathy. Conclusion. These observations suggest that MCP-1 may be involved in the pathogenesis of diabetic nephropathy. High-dose vitamin E may provide a novel form of therapy for the prevention of microvascular complications in type-1 diabetic patients.

References

American Diabetes Association, “Standards of medical care in diabetes—2007,” Diabetes Care, vol. 30, pp. S4–S41, 2007.
View at: Publisher Site | Google Scholar
H. H. Parving, R. Osterby, P. W. Anderson, and W. A. Hsueh, “Diabetic nephropathy,” in The Kidney, B. M. Brenner, Ed., pp. 1864–1892, WB Saunders, Philadelphia, Pa, USA, 5th edition, 1996.
View at: Google Scholar
C. E. Mogensen, “Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas,” Diabetologia, vol. 42, no. 3, pp. 263–285, 1999.
View at: Publisher Site | Google Scholar
M. E. Cooper, R. E. Gilbert, and G. Jerums, “Diabetic vascular complications,” Clinical and Experimental Pharmacology and Physiology, vol. 24, no. 9-10, pp. 770–775, 1997.
View at: Publisher Site | Google Scholar
M. E. Cooper, “Pathogenesis, prevention, and treatment of diabetic nephropathy,” The Lancet, vol. 352, no. 9123, pp. 213–219, 1998.
View at: Publisher Site | Google Scholar
T. Wada, K. Furuichi, N. Sakai et al., “Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy,” Kidney International, vol. 58, no. 4, pp. 1492–1499, 2000.
View at: Publisher Site | Google Scholar
F. Cipollone, M. Marini, M. Fazia et al., “Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 3, pp. 327–334, 2001.
View at: Google Scholar
T. Wada, H. Yokoyama, K. Furuichi et al., “Intervention of crescentic glomerulonephritis by antibodies to monocyte chemotactic and activating factor (MCAF/MCP-1),” The FASEB Journal, vol. 10, no. 12, pp. 1418–1425, 1996.
View at: Google Scholar
W. W. Tang, S. Yin, A. J. Wittwer, and M. Qi, “Chemokine gene expression in anti-glomerular basement membrane antibody glomerulonephritis,” American Journal of Physiology, vol. 269, no. 3, pp. F323–F330, 1995.
View at: Google Scholar
Yu. Natori, M. Sekiguchi, Z. Ou, and Ya. Natori, “Gene expression of CC chemokines in experimental crescentic glomerulonephritis (CGN),” Clinical & Experimental Immunology, vol. 109, no. 1, pp. 143–148, 1997.
View at: Publisher Site | Google Scholar
T. Wada, K. Furuichi, C. Segawa-Takaeda et al., “MIP-1 $α$ and MCP-1 contribute to crescents and interstitial lesions in human crescentic glomerulonephritis,” Kidney International, vol. 56, no. 3, pp. 995–1003, 1999.
View at: Publisher Site | Google Scholar
T. Wada, H. Yokoyama, S.-B. Su et al., “Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis,” Kidney International, vol. 49, no. 3, pp. 761–767, 1996.
View at: Publisher Site | Google Scholar
H. Yokoyama, T. Wada, K. Furuichi et al., “Urinary levels of chemokines (MCAF/MCP-1, IL-8) reflect distinct disease activities and phases of human IgA nephropathy,” Journal of Leukocyte Biology, vol. 63, no. 4, pp. 493–499, 1998.
View at: Google Scholar
I.-S. Park, H. Kiyomoto, S. L. Abboud, and H. E. Abboud, “Expression of transforming growth factor- $β$ and type IV collagen in early streptozotocin-induced diabetes,” Diabetes, vol. 46, no. 3, pp. 473–480, 1997.
View at: Publisher Site | Google Scholar
T. Furuta, T. Saito, T. Ootaka et al., “The role of macrophages in diabetic glomerulosclerosis,” American Journal of Kidney Diseases, vol. 21, no. 5, pp. 480–485, 1993.
View at: Google Scholar
B. A. Young, R. J. Johnson, C. E. Alpers et al., “Cellular events in the evolution of experimental diabetic nephropathy,” Kidney International, vol. 47, no. 3, pp. 935–944, 1995.
View at: Publisher Site | Google Scholar
R. A. K. Stahl, F. Thaiss, M. Disser, U. Helmchen, K. Hora, and D. Schlöndorff, “Increased expression of monocyte chemoattractant protein-1 in anti-thymocyte antibody-induced glomerulonephritis,” Kidney International, vol. 44, no. 5, pp. 1036–1047, 1993.
View at: Publisher Site | Google Scholar
C.-G. Ihm, “Monocyte chemotactic peptide-1 in diabetic nephropathy,” Kidney International. Supplement, vol. 60, pp. S20–S22, 1997.
View at: Google Scholar
P. Hovind, L. Tarnow, P. Rossing et al., “Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study,” British Medical Journal, vol. 328, no. 7448, pp. 1105–1108, 2004.
View at: Publisher Site | Google Scholar
M. Murussi, P. Baglio, J. L. Gross, and S. P. Silveiro, “Risk factors for microalbuminuria and macroalbuminuria in type 2 diabetic patients: a 9-year follow-up study,” Diabetes Care, vol. 25, no. 6, pp. 1101–1103, 2002.
View at: Publisher Site | Google Scholar
B. A. Perkins, L. H. Ficociello, K. H. Silva, D. M. Finkelstein, J. H. Warram, and A. S. Krolewski, “Regression of microalbuminuria in type 1 diabetes,” The New England Journal of Medicine, vol. 348, no. 23, pp. 2285–2293, 2003.
View at: Publisher Site | Google Scholar
F. Chiarelli, F. Cipollone, A. Mohn et al., “Circulating monocyte chemoattractant protein-1 and early development of nephropathy in type 1 diabetes,” Diabetes Care, vol. 25, no. 10, pp. 1829–1834, 2002.
View at: Publisher Site | Google Scholar
F. Cipollone, F. Chiarelli, A. Iezzi et al., “Relationship between reduced BCL-2 expression in circulating mononuclear cells and early nephropathy in type 1 diabetes,” International Journal of Immunopathology and Pharmacology, vol. 18, no. 4, pp. 625–635, 2005.
View at: Google Scholar
N. Banba, T. Nakamura, M. Matsumura, H. Kuroda, Y. Hattori, and K. Kasai, “Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy,” Kidney International, vol. 58, no. 2, pp. 684–690, 2000.
View at: Publisher Site | Google Scholar
S. Kiyici, E. Erturk, F. Budak et al., “Serum monocyte chemoattractant protein-1 and monocyte adhesion molecules in type 1 diabetic patients with nephropathy,” Archives of Medical Research, vol. 37, no. 8, pp. 998–1003, 2006.
View at: Publisher Site | Google Scholar
P. Gæde, H. E. Poulsen, H.-H. Parving, and O. Pedersen, “Double-blind, randomised study of the effect of combined treatment with vitamin C and E on albuminuria in type 2 diabetic patients,” Diabetic Medicine, vol. 18, no. 9, pp. 756–760, 2001.
View at: Publisher Site | Google Scholar
Y. Ishikawa, H. Sugiyama, E. Stylianou, and M. Kitamura, “Bioflavonoid quercetin inhibits interleukin-1-induced transcriptional expression of monocyte chemoattractant protein-1 in glomerular cells via suppression of nuclear factor- $κ$ B,” Journal of the American Society of Nephrology, vol. 10, no. 11, pp. 2290–2296, 1999.
View at: Google Scholar
Heart Outcomes Prevention Evaluation (HOPE) Study Investigators, “Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy,” The Lancet, vol. 355, no. 9200, pp. 253–259, 2000.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2008 Eid El-Shafey et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

347

Downloads

0

Citations